Dasiglucagon clinical trials
Also written ZP4207.
How each study uses dasiglucagon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 22 Mar 2021 · ZEGALOGUE · NDA 214231 (FDA, Drugs@FDA)
- European Union
- 24 Jul 2024 · Zegalogue · EMEA/H/C/006214 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
23 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 6
Zealand Pharma (15) · Steno Diabetes Center Copenhagen (2) · Novo Nordisk A/S (1) · Filip Krag Knop (1) · University Hospital, Gentofte, Copenhagen (1) · Massachusetts General Hospital (1) · Inreda Diabetic B.V. (1) · Insel Gruppe AG, University Hospital Bern (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dasiglucagon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsCompletedPhase 3Novo Nordisk A/SNCT06588504Written as DasiglucagonHow we know
- Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismCompletedPhase 3Zealand PharmaNCT03941236Written as dasiglucagonHow we know
- A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1DCompletedPhase 3Zealand PharmaNCT05378672Written as DasiglucagonHow we know
- Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismCompletedPhase 2/3Zealand PharmaNCT04172441Written as dasiglucagonHow we know
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop SystemWithdrawnPhase 2Inreda Diabetic B.V.NCT05454709Written as DasiglucagonHow we know
- A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismCompletedPhase 3Zealand PharmaNCT03777176Written as DasiglucagonHow we know
- Micro Glucagon During Exercise in Type 1 DiabetesWithdrawnEarly Phase 1Insel Gruppe AG, University Hospital BernNCT04192019Written as Micro-glucagonHow we know
- A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DMCompletedPhase 3Zealand PharmaNCT03895697Written as dasiglucagonHow we know
- Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated AdultsWithdrawnPhase 2Zealand PharmaNCT04824872Written as DasiglucagonHow we know
- Treatment of Post-bariatric HypoglycaemiaCompletedPhase 2Filip Krag KnopNCT04836273Written as DasiglucagonHow we know
- Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 DiabetesCompletedPhase 2Steno Diabetes Center CopenhagenNCT04764968Written as DasiglucagonHow we know
- Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenCompletedPhase 3Zealand PharmaNCT03667053Written as dasiglucagonHow we know
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsCompletedPhase 3Zealand PharmaNCT03378635Written as DasiglucagonHow we know
- Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DMCompletedPhase 3Zealand PharmaNCT03688711Written as DasiglucagonHow we know
- A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes MellitusCompletedPhase 3Zealand PharmaNCT03216226Written as dasiglucagonHow we know
- Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV AdministrationCompletedPhase 1Zealand PharmaNCT03735225Written as DasiglucagonHow we know
- Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 DiabetesCompletedPhase 2Steno Diabetes Center CopenhagenNCT04449692Written as DasiglucagonHow we know
- Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric BypassCompletedPhase 2University Hospital, Gentofte, CopenhagenNCT03984370Written as ZP4207How we know
- The Bihormonal iLet Bionic Pancreas Feasibility StudyCompletedPhase 2/3Massachusetts General HospitalNCT03840278Written as DasiglucagonHow we know
- ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02916251Written as ZP4207(dasiglucagon) glucagon analogueHow we know
See all 23 studies that test dasiglucagon →
Given beside what is tested · 1 — dasiglucagon is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 20, 2026.
Codes
What other systems call dasiglucagon · ClinicalTrials.gg INT001418
- MeSH (NLM) C000710373dasiglucagonOne source NLM
- UNII (FDA) AD4J2O47FQDASIGLUCAGONConfirmed FDA, NLM, Wikidata
- RxNorm 2535233One source FDA
- Wikidata Q106158304dasiglucagonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171918DasiglucagonOne source FDA
- DrugBank DB15226One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710373 | dasiglucagon | One source NLM |
| UNII (FDA) | AD4J2O47FQ | DASIGLUCAGON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2535233 | — | One source FDA |
| Wikidata | Q106158304 | dasiglucagon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171918 | Dasiglucagon | One source FDA |
| DrugBank | DB15226 | — | One source Wikidata |
Also registered as dasiglucagon hydrochloride (UNII YQX12245A9 · RxNorm 2535234).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.